ReviewCardiovascular & hematological disorders drug targets2026
A Review on Finerenone and Heart Failure with Preserved Ejection Fraction (HFpEF).
Review in Cardiovascular & hematological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHeart failure with preserved ejection fraction (HFpEF) accounts for about half of all heart failure cases and is difficult to treat because it has many causes and limited treatment options. Finerenone is a newer nonsteroidal mineralocorticoid receptor antagonist (MRA) that is more selective, distributes evenly between the heart and kidneys, and leads to fewer hormone-related side effects than older steroidal MRAs.
methodsThis review examines results from key clinical trials, such as FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF, as well as recent studies that have followed patients and explored how finerenone works in HFpEF and heart failure with mildly reduced ejection fraction (HFmrEF). Studies published between 2020 and 2025 were found using PubMed, Embase, Scopus, and the Cochrane Library.
resultsClinical trials found that finerenone reduced the risk of cardiovascular events, including heart failure hospitalizations and cardiovascular death, regardless of ejection fraction. Biomarker analysis showed lower NT-pro BNP levels, improved diastolic function, and less cardiac remodeling. Finerenone also had strong anti-inflammatory and antifibrotic effects, maintained renal safety, and caused less hyperkalemia than steroidal mineralocorticoid receptor antagonists (MRAs). These benefits appeared in all groups, no matter their age, sex, kidney function, or use of sodium-glucose cotransporter 2 (SGLT2) inhibitors. DISCUSSION: Finerenone provides cardiorenal protection by targeting key inflammatory and fibrotic pathways in HFpEF. Its favorable safety profile and additive effects with SGLT2 inhibitors support its integration into evolving guideline-directed therapy.
conclusionFinerenone is a significant step forward in treating HFpEF, as it provides both heart and kidney protection. Current studies will help identify which patients benefit most and how it affects long-term results in more people with HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.